ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
نویسندگان
چکیده
منابع مشابه
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
HIGHLIGHTS ASS2324 is a hybrid compound resulting from the juxtaposition of donepezil and the propargylamine PF9601N ASS2324 is a multi-target directed propargylamine able to bind to all the AChE/BuChE and MAO A/B enzymesASS2324 shows antioxidant, neuroprotective and suitable permeability propertiesASS2324 restores the scopolamine-induced cognitive impairment to the same extent as donepezil, an...
متن کاملP14: Mitochondria as a Target for Drug Therapy in Epilepsy
لطفاً به چکیده انگلیسی مراجعه شود.
متن کاملMulti-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the propargyl group from the PF 9601N, a potent and selective MAO B inhibitor. This compound is the most advanced anti-Alzheimer agent for preclinical studies identified in our laboratory.Derived from ASS234 both multipotent donepezil-indolyl (MTDL-1) and donepezil-pyridyl hybrids (MTDL-2) were designed and evaluated as...
متن کاملassessment of the effect of honey as a topical therapy for intra oral wound healing in rat.
چکیده ندارد.
15 صفحه اولNew multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol.
Alzheimer's disease (AD) is currently one of the most difficult and challenging diseases to treat. Based on the ‘multi-target-directed ligands’ (MTDLs) strategy, we designed and synthesised a series of new compounds against AD by combining the pharmacophores of resveratrol and clioquinol. The results of biological activity tests showed that the hybrids exhibited excellent MTDL properties: a sig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neuroscience
سال: 2016
ISSN: 1662-453X
DOI: 10.3389/fnins.2016.00294